<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03285711</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-437-4093</org_study_id>
    <nct_id>NCT03285711</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN)</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Multicenter Study Evaluating the Safety and Efficacy of Filgotinib and GS-9876 in Subjects With Lupus Membranous Nephropathy (LMN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of filgotinib and GS-9876 in
      adults with Lupus Membranous Nephropathy (LMN).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Urine Protein From Baseline (Day 1) to Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Urine protein will be assessed by urinary protein excretion during a 24-hour urine collection.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day 1) in Urine Protein at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>Urine protein will be assessed by urinary protein excretion during a 24-hour urine collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline (Day 1) in Estimated Glomerular Filtration Rate (eGFR) at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline (Day 1) in urine protein creatinine ratio (UPCR) at Week 16</measure>
    <time_frame>Baseline to Week 16</time_frame>
    <description>UPCR will be assessed by urine protein excretion during a 24-hour urine collection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Partial Remission at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Partial Remission is defined as urine protein excretion below &lt; 3 g/d and urine protein excretion decrease by ≥ 50% among participants with Baseline (Day 1) nephrotic range proteinuria [urine protein excretion ≥ 3 g/d]; or urine protein excretion decrease by ≥ 50% among participants with subnephrotic range proteinuria [urine protein excretion &lt; 3 g/d])</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Complete Remission</measure>
    <time_frame>Week 16</time_frame>
    <description>Complete Remission is defined as urine protein excretion below 0.5 g/day, with no hematuria.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Lupus Membranous Nephropathy</condition>
  <arm_group>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filgotinib + GS-9876 placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GS-9876 + filgotinib placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extended Blinded Treatment Phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on reduction in urinary protein excretion, participants will continue to receive their assigned blinded study treatment for an additional 20 weeks or continue to either study treatment per the Investigator's discretion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib</intervention_name>
    <description>200 mg tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Extended Blinded Treatment Phase</arm_group_label>
    <other_name>GS-6034</other_name>
    <other_name>GLPG0634</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876</intervention_name>
    <description>30 mg tablet administered orally once daily</description>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_label>Extended Blinded Treatment Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgotinib placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>GS-9876</arm_group_label>
    <arm_group_label>Extended Blinded Treatment Phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9876 placebo</intervention_name>
    <description>Tablet administered orally once daily</description>
    <arm_group_label>Filgotinib</arm_group_label>
    <arm_group_label>Extended Blinded Treatment Phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Male or female between 18 and 75 years of age, inclusive, at the time of initial
             informed consent

          -  Kidney biopsy within the 36 months prior to screening with a histologic diagnosis of
             LMN (International Society of Nephrology [ISN] and the Renal Pathology Society [RPS]
             2003 classification of lupus nephritis), either Class V alone, or Class V in
             combination with Class II.

          -  Urine protein excretion ≥ 1.5 grams per day

          -  Estimated glomerular filtration rate (eGFRMDRD) ≥ 40 mg/min/1.73m^2 based on the MDRD
             formulation at screening

          -  No evidence of active or latent TB as assessed during screening

        Key Exclusion Criteria:

          -  Prior treatments as follows:

               -  Previous treatment with a JAK inhibitor within 3 months of Day 1

               -  Use of rituximab or other selective B lymphocyte depleting agents (including
                  experimental agents) within 6 months of Day 1. Enrollment is permitted if the
                  last dose was given &gt; 6 months and CD19-positive B cells are detectable at
                  Screening.

          -  Use of any concomitant prohibited medications as described in the protocol

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (UCSD)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Of Florida, Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Nephrology Research Institute</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill / UNC School of Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research Inc.</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Temple University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, University Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Center of South Texas</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78332</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2017</study_first_submitted>
  <study_first_submitted_qc>September 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2017</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

